Notable Labs
YC W15YC Top CompanySan Francisco, US · Founded 2014 · Delaware corporation · 40 employees · Public · Hiring · 10 known investors
Notable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.
BiotechHealthtechMedical DevicesDrug discoveryOncologyUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (W15)
Notable Labs was founded in 2014 by Matthew De Silva and Pete Quinzio.
MD
Matthew De Silvain𝕏Founder & Executive Chairman2020–2023Venture Partner, Health at Builders VC30 Under 30 2017
PQ
Pete QuinzioinFounder
Investors · 10
11.2 CapitalLas Vegas · $500K – $3M
Builders VCSan Franciscovia Matthew De Silva · board
FundersClubSan Francisco · $250K – $5M
Hemisphere Ventures LLCMckinney
Lifeforce CapitalChevy Chase · $500K – $5M
Y CombinatorSan Francisco · $500K
Amplify PartnersreportedMenlo Park · $500K – $5M
B4 Capitalreported$10M – $50Mvia Adam Seabrook · board
Founders FundreportedSan Francisco · $500K – $5M
Locus VenturesreportedPalo Alto
Reported raises · per SEC filings
Form D private placements$82.2M disclosed across 6 rounds · 2014–2023
▶$10.3MraisedMar 2023 · 26 investors · BiotechnologyRule 506(b)
▶$10.3MraisedMar 2023 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph WagnerExecutive Officer
- Matthew De SilvaDirector
- Adam SeabrookDirector
- James KimDirector
- Thomas BockExecutive Officer, Director
- Offering amount
- $10.3M
- Amount sold
- $10.3M
- Sales commissions
- $310.1K
- Placement agents
- JMP Securities LLC
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.1MraisedJul 2022 · 19 investors · BiotechnologyRule 506(b)
▶$10.1MraisedJul 2022 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James KimDirector
- Adam SeabrookDirector
- Matthew De SilvaDirector
- Thomas BockExecutive Officer, Director
- Offering amount
- $10.5M
- Amount sold
- $10.1M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$39.8MraisedDec 2019 · 37 investors · BiotechnologyRule 506(b)
▶$39.8MraisedDec 2019 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew De SilvaExecutive Officer, Director
- Michael HorowitzExecutive Officer
- James KimDirector
- Peter QuinzioExecutive Officer, Director
- Offering amount
- $44M
- Amount sold
- $39.8M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$14.8MraisedAug 2017 · 95 investors · Other Health CareRule 506(c)
▶$14.8MraisedAug 2017 · 95 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- James KimDirector
- Matthew De SilvaExecutive Officer, Director, Promoter
- Pete QuinzioExecutive Officer, Director, Promoter
- Amanda HermannExecutive Officer
- Offering amount
- $17.7M
- Amount sold
- $14.8M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
▶$2.7MraisedMar 2017 · 23 investors · BiotechnologyRule 506(b)
▶$2.7MraisedMar 2017 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter QuinzioExecutive Officer
- Matthew De SilvaExecutive Officer, Director
- Offering amount
- $2.7M
- Amount sold
- $2.7M
- Proceeds to insiders
- $300K
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$4.5MraisedMay 2016 · 40 investors · BiotechnologyRule 506(b)
▶$4.5MraisedMay 2016 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew De SilvaExecutive Officer, Director
- Peter QuinzioExecutive Officer
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- Proceeds to insiders
- $300K
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
The YC application· Winter 2015 batch
In the news
Frequently asked questions
- What does Notable Labs do?
- Notable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.
- Who founded Notable Labs?
- Notable Labs was founded by Matthew De Silva, Pete Quinzio in 2014.
- Who are Notable Labs's investors?
- Notable Labs's investors include 11.2 Capital, Builders VC, FundersClub, Hemisphere Ventures LLC, Lifeforce Capital, Y Combinator, Amplify Partners, B4 Capital and 2 more.
- How much funding has Notable Labs raised?
- Notable Labs has disclosed $82.2M raised across 6 rounds.
- Where is Notable Labs headquartered?
- Notable Labs is headquartered in San Francisco, US.